Comparative Pharmacology
Head-to-head clinical analysis: NEOPASALATE versus TRECATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOPASALATE versus TRECATOR.
NEOPASALATE vs TRECATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Para-aminosalicylic acid (PAS) competitively inhibits the conversion of aminobenzoic acid to dihydrofolate, thereby inhibiting Mycobacterium tuberculosis growth.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the formation of the initiation complex and causing misreading of mRNA.
4-6 g orally twice daily; maximum 12 g/day.
15-20 mg/kg/day orally once daily; maximum 1 g/day.
None Documented
None Documented
Terminal elimination half-life is 2.5–4.5 hours in adults, prolonged in renal impairment.
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged in hepatic impairment; clinically relevant for once-daily or thrice-weekly dosing
Primarily renal (≥80% as unchanged drug and acetylated metabolite); minor fecal elimination (<5%).
Renal: 70-80% as unchanged drug; fecal: <20%; biliary: minor
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent